Related Experiment Videos
Absence of peripheral-type benzodiazepine binding sites in renal carcinoma: a potential biochemical marker
Y Katz1, B Moskovitz, D R Levin
1Department of Pharmacology, Faculty of Medicine, Technion-Israel Institute of Technology, Haifa.
Abstract:
In an attempt to identify a tumour marker, we investigated peripheral-type benzodiazepine binding sites (PBS) in kidney specimens obtained from patients who underwent nephrectomy due to a renal mass. [3H]PK 11195, an isoquinoline carboxamide derivative, was used as a ligand. Binding assays were conducted on samples of membrane homogenate taken from both the healthy portion and the tumour site of the kidney. It was found that binding characteristics of benign tumours and normal kidney tissues were not significantly different, i.e. equilibrium dissociation constants of 2.20 +/- 0.73 and 2.38 +/- 0.98 nM, respectively, and maximal number of binding sites of 3190 +/- 1081 and 4189 +/- 998 fmol/mg protein, respectively. In contrast, no PBS were detectable in renal carcinoma. The absence of PBS in malignant renal tissues may serve as a biochemical marker for tumours of the kidney.
Insights
Peripheral-type benzodiazepine binding sites (PBS) were investigated as a potential kidney tumour marker. Absence of PBS in renal carcinoma suggests their utility as a biochemical marker for kidney cancer detection.
Area of Science:
- Oncology
- Biochemistry
- Medical Diagnostics
Background:
- Renal masses require accurate diagnostic markers.
- Peripheral-type benzodiazepine binding sites (PBS) are implicated in various cellular processes.
Purpose of the Study:
- To investigate peripheral-type benzodiazepine binding sites (PBS) as a potential tumor marker for kidney cancer.
- To differentiate between normal kidney tissue, benign tumors, and malignant renal tumors using PBS.
Main Methods:
- Kidney specimens from nephrectomy patients were analyzed.
- Binding assays were performed using [3H]PK 11195 ligand to quantify PBS.
- Membrane homogenates from healthy, benign tumor, and malignant tumor sites were compared.
Main Results:
- Benign kidney tumors and normal kidney tissues exhibited similar PBS binding characteristics.
- No detectable peripheral-type benzodiazepine binding sites (PBS) were found in renal carcinoma samples.
- Significant difference in PBS levels between malignant and benign/normal kidney tissues was observed.
Conclusions:
- The absence of peripheral-type benzodiazepine binding sites (PBS) in renal carcinoma suggests a potential diagnostic role.
- PBS may serve as a specific biochemical marker for identifying malignant kidney tumors.
- Further research is warranted to validate PBS as a reliable tumor marker for kidney cancer.